Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    An NIH-wide announcement about changing terminology was added above the ClinicalTrials.gov 403 error page. The displayed site revision advanced from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T21:53:22.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The site revision number in the footer changed from `v3.7.0` to `v3.7.1` on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-06T21:39:36.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record content with a standard access-denied screen. This reflects an access restriction rather than changes to the study data.
    Difference
    19%
    Check dated 2026-09-22T22:39:42.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The page’s revision label was updated from v3.6.6 to v3.7.0, signaling an underlying platform update. This update appears to be a backend/template change rather than affecting the study content or user-facing details.
    Difference
    0.1%
    Check dated 2026-09-15T20:35:13.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.5 to v3.6.6. This signals a minor maintenance update without changing study details or core content.
    Difference
    0.1%
    Check dated 2026-09-01T18:10:47.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    A funding attribution line for 2016 U.S. NIH Grant/Contract was added under Other Study ID Numbers, providing the source of support for the study. This addition adds administrative funding context without altering trial design, endpoints, or eligibility.
    Difference
    0.1%
    Check dated 2026-08-25T19:33:59.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.